Background: Somatostatin (SST) is a neuropeptide expressed in a subtype of gamma-aminobutyric acid (GABA) interneurons that target the dendrites of pyramidal neurons. We previously reported reduced levels of SST gene and protein expression in the postmortem amygdala of subjects with major depressive disorder (MDD). This reduction was specific to female subjects with MDD.
INTRODUCTION
Somatostatin (SST) is a neuromodulatory peptide expressed in a subtype of GABA neurons that specifically inhibit the dendritic compartment of excitatory pyramidal neurons (Viollet et al., 2008) . Reduced SST expression has consistently been reported across several psychiatric [e.g. (Agren & Lundqvist, 1984; Bissette et al., 1986; Kling et al., 1993; Konradi et al., 2011; Molchan et al., 1993; Morris, Hashimoto, & Lewis, 2008; Sibille, Morris, Kota, & Lewis, 2011; Tripp, Kota, Lewis, & Sibille, 2011) ] and neurodegenerative brain disorders [e.g. (Davies & Terry, 1981; Dupont et al., 1982; Gahete et al., 2010) ]. We Abbreviations: CT, central traverse; DLPFC, dorsolateral prefrontal cortex; GABA, gamma-aminobutyric acid; LT, lateral traverse; MDD, major depressive disorder; MT, medial traverse; PMI, postmortem interval; PV, parvalbumin; RIN, RNA integrity number; ROI, region of interest; sgACC, subgenual anterior cingulate cortex; SST, somatostatin; VIP, vasoactive intestinal peptide previously reported reduced SST gene expression in major depressive disorder (MDD). This pattern of reduced SST gene expression in MDD was found across several corticolimbic brain regions, including the dorsolateral prefrontal cortex , the subgenual anterior cingulate cortex (sgACC) (Tripp et al., 2011) , and the lateral and basomedial nuclei of the amygdala (Guilloux et al., 2012) . There was a sex difference in our findings that mimics the female vulnerability to MDD.
Specifically, we found more robust SST reduction in female subjects in the sgACC (Seney, Chang et al., 2013 ) and a reduction only in females in the amygdala (Guilloux et al., 2012) [see (Sibille et al., 2009) for no change in SST expression in the amygdala of male MDD subjects].
SST cells represent ∼18-20% of interneurons and exhibit a laminarspecific pattern of expression in the cortex (Lewis, Campbell, & Morrison, 1986; McDonald & Mascagni, 2002; Weckbecker et al., 2003) . However, there is no laminar organization in the lateral and basolateral nuclei of the amygdala, and SST cells are uniformly distributed (Muller, Mascagni, & McDonald, 2007 Graebenitz, & Pape, 2010) , similar to SST cells in layer 4 of the cortex (Ma et al., 2006) . As observed in the cortex, basolateral amygdala SST cells predominantly innervate the distal dendrites of excitatory pyramidal cells. Additionally, a small percentage of SST cells innervate other interneurons (Muller et al., 2007) . Interestingly, recent work has identified a novel subpopulation of basolateral amygdala SST cells that send long-range projections to the basal forebrain (McDonald, Mascagni, & Zaric, 2012) , although the electrophysiological properties and function of these long-range targeting cells remain unknown.
Here, we used in situ hybridization to quantify SST mRNA levels in the amygdala of MDD subjects for which we had a priori information of reduced SST expression, as measured by gene array and quantitative PCR in combined gray matter samples (Guilloux et al., 2012; Tripp et al., 2011) . Identifying whether the SST reduction is based on reduced SST per cell or reduced density of SST-positive cells has implications for mechanisms of disease and for therapeutic approaches. Thus, we characterized the specificity of the reduced SST in the lateral, basolateral and basomedial nuclei of the amygdala using measurements of the amount of SST expression per SST-positive cell and density of SSTpositive cells in each amygdala region.
MATERIAL AND METHODS

Human postmortem subjects
Brain samples were obtained after consent was provided by next of kin during autopsies conducted at the Allegheny County Medical Examiner's Office (Pittsburgh, USA). The University of Pittsburgh's Institutional Review Board and Committee for Oversight of Research Involving the Dead approved all procedures. An independent committee of experienced clinical research scientists made consensus DSM-IV diagnoses for each subject using structured interviews with family members as well as review of medical records and toxicology results; the absence of psychiatric diagnoses was confirmed in control subjects using the same approach (Glantz, Austin, & Lewis, 2000) .
A cohort of ten subject pairs was created consisting of female subjects with MDD and female control subjects (Table 1) . To control for biological and experimental variance, subjects with MDD were matched to comparison subjects for race and as closely as possible for age. All selected brains were analyzed for adequate brain pH (>6.4) and RNA integrity by optical density (OD ≥1.6) and Agilent bioanalyzer analysis (Agilent Technologies, Palo Alto, CA; RIN expert scoring system ≥7) as previously described (Sibille et al., 2009) . Subject groups did not differ in mean age, postmortem interval (PMI), RNA integrity number (RIN), and RNA ratio (p > .05). There was a significant effect of group on brain pH, which we accounted for by using pH as a covariate in our statistical model (see Section 2.5). Subjects were selected for rapid modes of death and short agonal phases to limit the effect of these factors on RNA quality and pH (Beneyto, Sibille, & Lewis, 2008) , while subjects with advanced disease stages (i.e., cancer, neurodegenerative disorders) were excluded. This cohort is a subset of a larger cohort used previously, and subjects were selected to enrich the cohort in MDD subjects with robust reduction in SST expression (Guilloux et al., 2012) since the aim of this study was not to confirm the reduction of SST in MDD, but rather to further determine the nature of the reduction (i.e., whether the reduction is specific to a particular nucleus of the amygdala, whether there is loss of SST-positive cells, or reduction in SST per cell).
In situ hybridization
Templates for the synthesis of the antisense and sense riboprobes were generated by PCR using specific primers to amplify a 337 base pair fragment of human SST. These fragments corresponded to bases 112-448 of the human SST gene (GenBank NM_001048). 35 S-labeled riboprobes were generated by in vitro transcription and hybridized to two sections (separated by 140 m) from each subject. In situ hybridization probes, methods, and analyses were performed as previously described (Guilloux et al., 2012; Morris et al., 2008; Seney et al., 2015) . Matched subjects were processed together to reduce experimental variance.
Each slide was randomly coded, such that subject number and diagnosis were unknown to the experimenter. Sections were transilluminated and bright-field photomicrographs were captured, digitized, and analyzed with Microcomputer Imaging Device (MCID; Imaging Research, Inc., London, Ontario, Canada) software. The sections as well as [ 14 C] standards were exposed on the same BioMax MR film (Kodak, Rochester, NY, USA) for 3 days and analyzed using MCID.
Evaluation of mRNA expression at the cellular level was performed by determining silver grain accumulation on emulsion-dipped, cresyl violet counterstained sections. After digitizing each autoradiographic film section, the in situ hybridized slides were coated with liquid emulsion at 43°C (KODAK Autoradiography Emulsion, Type NTB for light Microscope Autoradiography). Slides were dipped for 1 min using an automated dipping machine. Slides were then wrapped in aluminum foil in a plastic box and incubated at 4°C for 12 days. The coated slides were then dipped for 4 min in developer, 1 min in Milli-Q water, and 8 min in fixer. Emulsion-coated slides were counterstained immediately after being developed. Tissue sections were stained for 10 s with 0.5% cresyl violet solution, followed by two rinses in Milli-Q water.
Slides were then dehydrated with a graded ethanol series, followed by xylene, and coverslipped with Permount. Developed slides counterstained with cresyl violet were superimposed onto images captured before dipping (bright-field digitized image of the dried slides) to draw contours of each nucleus (lateral, basal, and mediobasal nucleus) onto the dipped slides. Amygdala regions were then confirmed in adjacent sections stained for acetylcholinesterase and Nissl substance.
Sampling strategy for each amygdala nucleus
Using the MCID system coupled to a microscope equipped with a motor-driven stage, a region of interest (ROI) (Fig. 1B and C) was defined for each nucleus by a square including the nucleus. Since these amygdala nuclei are irregular in shape, the ROI squares were placed such that each irregularly shaped nucleus fell within its respective ROI square (see Fig. 1 ). Three traverses (from the dorsal surface to the ventral surface) were placed in each ROI and two sections were analyzed Ten sampling bins were placed in each traverse from 10 to 90% from the dorsal to the ventral surface of the traverse. Due to the relatively smaller size of the BM nucleus, bins were placed to cover the entire nucleus, from 10 to 90% of the distance from the lateral to the medial border and from 10 to 90% from the dorsal to the ventral border of this nucleus per subject (separated by 140 m). For the lateral nucleus, the lateral traverse (LT) was drawn at 20% of the distance from the lateral to the medial border, the medial traverse (MT) at 50%, and the central traverse (CT) at 90%. For the basolateral nucleus, the LT was drawn at 20%, the MT at 30%, and the CT at 70% of the distance from the lateral to the medial border of the nuclei. Ten sampling frames (500 × 500 m) were placed in each of the three traverses (for a total of 30 sampling frames per nucleus) from 10 to 90% from the dorsal to ventral surface ( Fig. 1B and C) . Due to the relatively smaller size of the basomedial nucleus, bins were placed to cover the entire nucleus, from 10 to 90% of the distance from the lateral to the medial border and from 10 to 90% from the dorsal to the ventral border of this ROI.
TA B L E 1 Subject characteristics
Major depression group
Density of SST-positive cell clusters and expression of SST mRNA per cluster
Since RNase A treatment during the in situ hybridization procedure degrades Nissl-stainable substances within the cytoplasm, it was not possible to draw contours around the soma of neurons. Thus, we used the pattern of grain clusters to identify SST-positive cells. We divided the SST-positive neurons into three major categories [types 1 (small spherical), 2 (large multipolar), and 3 (fusiform); as in (Sorvari et al., 1995) ]. Within each cell type, there was some heterogeneity with regard to the soma size and the number and caliber of the dendrites. 
Statistical analysis
To determine relevant scale covariates to include in the analysis of Tables 1 and 2 for details on statistics associated with covariate testing.
The modified Bonferroni-Holm method was used to correct for testing of multiple covariates. pH was the most consistent covariate used in the ANCOVA models, as pH is significantly higher in MDD compared to control (p < .001). Uncorrected ANCOVA p-values are reported for the analyses comparing in situ hybridization measures in controls versus MDD subjects, as we have a priori information of reduced tissue level SST expression in MDD in these same subjects.
RESULTS
We previously reported significantly reduced SST expression in MDD by qPCR and Western Blotting in the basolateral complex of the amygdala and by in situ hybridization in the lateral and basomedial nuclei of the amygdala (Guilloux et al., 2012) . In order to determine if all or a subset of SST neurons were affected in the lateral, basolateral, and basomedial nuclei of the basolateral complex of the amygdala, we determined (1) the density of SST-positive cells in each amygdala nucleus and (2) the SST mRNA levels per neuron by assessing the ratio of the area covered by silver grains in SST silver grain clusters.
MDD subjects have lower density of detectable SST-positive cells in the amygdala
We found a general reduction in the density of SST-positive clusters in MDD subjects in all three nuclei of the amygdala examined (lateral, basolateral, basomedial). Refer to (Fig. 3A) . This same pattern was found when the analysis was split by cluster size.
There was a 34% reduction in the density of large clusters (p < .02) and a 47% reduction in the density of small clusters (p < .005) in the lateral nucleus in MDD subjects. In the basolateral nucleus, there was a 40% reduction in the density of large clusters (p < .01) and a 43% reduction in the density of small clusters (p < .002) in MDD subjects. Similarly, there was a 40% reduction in density of large clusters (p < .004) and a 47% reduction in density of small clusters (p < .004) in the basomedial nucleus in MDD subjects. In parallel, we found no significant reduction in the density of cresyl violet stained cell bodies (both SST-positive and SST-negative combined; see Supplementary Fig. 1 ).
MDD subjects have reduced SST mRNA per cell only in the basomedial nucleus of the amygdala
As a measure of the expression of SST per SST-positive cell, we calculated the ratio of the area covered by silver grains for the small and large clusters. Refer to Table 3 for a summary of statistical results. In the basomedial nucleus, there was a 25% reduction in the ratio of area covered by silver grains per cluster (small and large clusters combined)
in MDD subjects compared to controls (p < .04; Fig. 3B ). We found this same result when we split the analysis by cluster size. Specifically, the ratio of the area covered by silver grains per cluster was reduced by 20% in large clusters (p < .04) and by 32% in small clusters (p < .01) in MDD subjects compared to controls. MDD subjects and con- (Fig. 3B) .
DISCUSSION
Reduced SST in MDD across corticolimbic brain regions
In addition to reduced SST expression in the amygdala of MDD subjects (as reported here and in (Guilloux et al., 2012) ), we previously showed that SST expression is reduced in other corticolimbic brain regions in subjects with MDD, namely the sgACC (Seney et al., 2015; Tripp et al., 2011) ) and dorsolateral prefrontal cortex (DLPFC (Seney, Chang et al., 2013) ). Thus, the reduced SST in MDD subjects appears to be a general finding as opposed to specific to the amygdala. Whether SST is reduced in additional corticolimbic or other brain regions of patients with MDD (e.g., the hippocampus) is unknown. We have used a strategy similar to the one used in the current study to examine the specificity of reduced SST in the sgACC of subjects with MDD. In contrast to the results presented here in the amygdala, we reported a robust reduction in SST mRNA expression per cell across cortical layers, and surprisingly no change in the density of SST-positive cells in the sgACC in subjects with MDD (Seney et al., 2015) . Thus, the reduced tissuelevel SST expression may occur through different mechanisms across corticolimbic brain regions. Using preclinical chronic stress models in mice, we showed that SST cells are selectively vulnerable to biological adversity, specifically affecting proteostasis, also known as endoplasmic reticulum (ER) stress (Lin & Sibille, 2015) . The outcome of such an event is reduced expression of non-essential genes, leading to cell death in somatic tissue and to loss of cellular phenotype in nondividing neurons (Roussel et al., 2013) . If applicable to human subjects, it is conceivable that the results in the amygdala represent a more severe phenotype compared to the sgACC. For instance, we may be be at play. We previously showed in rodent models that the expression of SST and other GABA-related neurons are affected by sex-related factors, namely circulating hormones and XY-related genetic factors (Seney, Chang et al., 2013; Seney, Ekong et al., 2013) , and consistent sex differences in gene expression are observed in the amygdala between mice and humans (Lin, Lewis, & Sibille, 2011) . Moreover, we found that the reduced expression of SST was more robust in female compared to male subjects in the sgACC (Seney, Chang et al., 2013) , and only female MDD subjects have reduced SST expression in the amygdala (Guilloux et al., 2012; Sibille et al., 2009) . Together, this suggests that sex-related factors may mediate the SST cellular pathology in MDD, a hypothesis that is of great interest, in view of the increased vulnerability of women to develop MDD (Kessler et al., 2005; Kornstein et al., 2000) .
Effects of reduced SST on local and amygdala circuitry
We previously found that SST expression is significantly decreased in the lateral and the basomedial nuclei in female MDD subjects compared to controls (Guilloux et al., 2012) . The lateral nucleus receives major input from the sensory cortex and the sensory thalamus and sends heavy projections to most other amygdala nuclei (Pitkanen, Savander, & LeDoux, 1997) there is a reduction in inhibitory GABA signaling in these amygdala nuclei as well. However, in our previous study comparing gene expression in the amygdala of female MDD subjects and controls (Guilloux et al., 2012) , we observed a reduction in several GABA-related transcripts, including the GABA synthesizing enzyme, glutamate decarboxylase 1 (GAD1), and the GABA receptor subunit, GABRA1; this suggests that there may indeed be reduced inhibition in these amygdala nuclei in female MDD subjects. Future studies may follow-up by using in situ hybridization for GAD1 or GAD2 in MDD and control subjects to achieve more spatial resolution.
Specificity of reduced SST
Reduced SST expression has been reported across brain regions in MDD but also in schizophrenia (Morris et al., 2008) , bipolar disorder (Sibille et al., 2009 ), Alzheimer's disease (Gahete et al., 2010) , and during normal aging (Glorioso, Oh, Douillard, & Sibille, 2011) . Low SST interacts in a complex biological landscape of additional interacting pathological modules with specific environmental factors and developmental trajectories for each of these disorders (Glorioso et al., 2011; Guilloux et al., 2012) . At the cell and local circuit levels, the specific consequence of low SST will depend on: (1) whether all SST neurons are affected, (2) whether deficits extend to altered levels of coexpressed neuromodulatory peptides within those cell populations (i.e., is there also decreased expression of neuropeptide Y and/or cortistatin), (3) whether GABA function itself is affected (see above), and (4) 
Limitations
Some of the limitations of these results are inherent to the investigation of heterogeneous human psychiatric disease cohorts and of postmortem brain samples. Large numbers of clinical, demographic, and technical parameters have to be taken into consideration, and results are mostly correlative and cannot provide insights into developmental processes in MDD. We used fairly stringent criteria for inclusion of covariates, only including those that survived after correction for multiple testing. Additionally, since we assessed effects of suicide and antidepressant use in only MDD subjects (ten subjects), this reduced the probability of detecting differences. Our smaller cohort size was chosen to evaluate the specificity of SST reduction, and was not powered to evaluate relevant modulators such as age (Tripp et al., 2011) .
CONCLUSION
Here, we used postmortem brain samples from female MDD subjects with known reductions in amygdala SST expression at the gene and protein level to characterize whether there was a reduction in the density of SST-positive neurons and/or a reduction of SST mRNA expression per neuron. Of note, we only examined females here, as male MDD subjects showed no change in SST mRNA (Sibille et al., 2009 ).
Results demonstrate a general reduction in the density of detectable SST-positive neurons in the lateral, basolateral, and basomedial nuclei, whereas a reduction in SST mRNA per neuron was only detected in the basomedial nucleus of the amgydala in MDD subjects. The relative density of all cells in each amygdala region did not differ between MDD and control subjects. Together, this suggests a potential change (or loss)
in SST cell phenotype in MDD subjects rather than fewer SST-positive neurons. 
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